X0306 4 2021-09-23 0 0001000694 NOVAVAX INC NVAX 0001219871 MOTT DAVID M C/O NOVAVAX, INC. 21 FIRSTFIELD ROAD GAITHERSBURG MD 20878 1 0 0 0 Common Stock 2021-09-23 4 S 0 5728 251.3216 D 59233 D Common Stock 2021-09-23 4 S 0 7557 252.5589 D 51676 D Common Stock 2021-09-23 4 S 0 7744 253.4614 D 43932 D Common Stock 2021-09-23 4 S 0 2732 254.4631 D 41200 D Common Stock 2021-09-23 4 S 0 1200 255.3835 D 40000 D The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.92 to $251.87, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.98 to $252.91, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $253.00 to $253.97, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.06 to $255.05, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.11 to $255.60, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. /s/ John A. Herrmann III, Attorney-in-Fact 2021-09-24